Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.

Böttcher M, Renner K, Berger R, Mentz K, Thomas S, Cardenas-Conejo ZE, Dettmer K, Oefner PJ, Mackensen A, Kreutz M, Mougiakakos D.

Oncoimmunology. 2018 Mar 26;7(7):e1445454. doi: 10.1080/2162402X.2018.1445454. eCollection 2018.

2.

Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions.

Spriewald BM, Bach C, Zingsem J, Strobel J, Winkler J, Mackensen A, Roesler W.

Bone Marrow Transplant. 2018 Jun;53(6):791-794. doi: 10.1038/s41409-018-0220-7. Epub 2018 May 24. No abstract available.

3.

Anatomy of a glacial meltwater discharge event in an Antarctic cove.

Meredith MP, Falk U, Bers AV, Mackensen A, Schloss IR, Ruiz Barlett E, Jerosch K, Silva Busso A, Abele D.

Philos Trans A Math Phys Eng Sci. 2018 Jun 28;376(2122). pii: 20170163. doi: 10.1098/rsta.2017.0163.

4.

Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.

Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S, Zimmermann R, Zingsem J, Strobel J, Mackensen A, Mautner J, Moosmann A, Gerbitz A.

J Transl Med. 2018 May 9;16(1):124. doi: 10.1186/s12967-018-1498-3.

5.

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.

Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, Bittenbring JT, Neumann F, Boxhammer R, Nolting J, Bisht S, Böttcher M, Jitschin S, Hoffmann MH, Balzer H, Beier F, Gezer D, Dudziak D, Gelse K, Hennig FF, Pallasch CP, Spriewald B, Mackensen A, Bruns H.

Leukemia. 2018 Mar 28. doi: 10.1038/s41375-018-0114-0. [Epub ahead of print]

PMID:
29654274
6.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
7.

IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.

Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A, Mougiakakos D.

Oncotarget. 2018 Feb 7;9(17):13125-13138. doi: 10.18632/oncotarget.24442. eCollection 2018 Mar 2.

8.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
9.

BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K.

J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.

10.

Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.

Grafe C, Semrau S, Hein A, Beckmann MW, Mackensen A, Dörje F, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Feb;391(2):219-229. doi: 10.1007/s00210-017-1456-2. Epub 2018 Jan 2.

PMID:
29294142
11.

Visualizing Single-Cell Secretion Dynamics with Single-Protein Sensitivity.

McDonald MP, Gemeinhardt A, König K, Piliarik M, Schaffer S, Völkl S, Aigner M, Mackensen A, Sandoghdar V.

Nano Lett. 2018 Jan 10;18(1):513-519. doi: 10.1021/acs.nanolett.7b04494. Epub 2017 Dec 19.

PMID:
29227108
12.

GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation.

Tittlbach H, Schneider A, Strobel J, Zimmermann R, Maas S, Gebhardt B, Rauser G, Mach M, Mackensen A, Winkler TH, Winkler J.

J Transl Med. 2017 Nov 7;15(1):228. doi: 10.1186/s12967-017-1330-5.

13.

Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.

Heidkamp GF, Sander J, Lehmann CHK, Heger L, Eissing N, Baranska A, Lühr JJ, Hoffmann A, Reimer KC, Lux A, Söder S, Hartmann A, Zenk J, Ulas T, McGovern N, Alexiou C, Spriewald B, Mackensen A, Schuler G, Schauf B, Forster A, Repp R, Fasching PA, Purbojo A, Cesnjevar R, Ullrich E, Ginhoux F, Schlitzer A, Nimmerjahn F, Schultze JL, Dudziak D.

Sci Immunol. 2016 Dec 16;1(6). pii: eaai7677. doi: 10.1126/sciimmunol.aai7677. Epub 2016 Dec 16.

PMID:
28783692
14.

Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13.

Resheq YJ, Menzner AK, Bosch J, Tickle J, Li KK, Wilhelm A, Hepburn E, Murihead G, Ward ST, Curbishley SM, Zimmermann HW, Bruns T, Gilbert DF, Tripal P, Mackensen A, Adams DH, Weston CJ.

J Immunol. 2017 Sep 1;199(5):1672-1681. doi: 10.4049/jimmunol.1600466. Epub 2017 Jul 24.

PMID:
28739875
15.

Sunitinib does not impair natural killer cell function in patients with renal cell carcinoma.

Moeckel J, Staiger N, Mackensen A, Meidenbauer N, Ullrich E.

Oncol Lett. 2017 Jul;14(1):1089-1096. doi: 10.3892/ol.2017.6187. Epub 2017 May 17.

16.

Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation.

Bach C, Steffen M, Roesler W, Winkler J, Mackensen A, Stachel KD, Metzler M, Spriewald BM.

Blood Cancer J. 2017 Jun 2;7(6):e566. doi: 10.1038/bcj.2017.42. No abstract available.

17.

[Recent development of hypertension and acute renal failure in a 59-year-old woman].

Uebner M, Jacobi J, Schmidt D, Büttner-Herold M, Mackensen A, Spriewald BM.

Internist (Berl). 2017 Dec;58(12):1319-1323. doi: 10.1007/s00108-017-0269-1. German.

PMID:
28555379
18.

CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D.

Bruns H, Böttcher M, Qorraj M, Fabri M, Jitschin S, Dindorf J, Busch L, Jitschin R, Mackensen A, Mougiakakos D.

Leukemia. 2017 Apr;31(4):985-988. doi: 10.1038/leu.2016.378. Epub 2016 Dec 23. No abstract available.

PMID:
28008175
19.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M.

Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15.

20.

Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Henrich FC, Singer K, Poller K, Bernhardt L, Strobl CD, Limm K, Ritter AP, Gottfried E, Völkl S, Jacobs B, Peter K, Mougiakakos D, Dettmer K, Oefner PJ, Bosserhoff AK, Kreutz MP, Aigner M, Mackensen A.

Oncoimmunology. 2016 Jun 10;5(8):e1184802. doi: 10.1080/2162402X.2016.1184802. eCollection 2016 Aug.

21.

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.

Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.

Leukemia. 2017 Feb;31(2):470-478. doi: 10.1038/leu.2016.214. Epub 2016 Aug 1.

PMID:
27479178
22.

The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia.

Finkel P, Frey B, Mayer F, Bösl K, Werthmöller N, Mackensen A, Gaipl US, Ullrich E.

Oncoimmunology. 2016 Jun 7;5(6):e1101206. doi: 10.1080/2162402X.2015.1101206. eCollection 2016 Jun.

23.

Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus.

Gerstner S, Köhler W, Heidkamp G, Purbojo A, Uchida S, Ekici AB, Heger L, Luetke-Eversloh M, Schubert R, Bader P, Klingebiel T, Koehl U, Mackensen A, Romagnani C, Cesnjevar R, Dudziak D, Ullrich E.

J Leukoc Biol. 2016 Dec;100(6):1297-1310. Epub 2016 Jun 28.

PMID:
27354408
24.

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T.

J Clin Oncol. 2016 Jul 20;34(21):2484-92. doi: 10.1200/JCO.2015.65.7171. Epub 2016 May 23.

PMID:
27217449
25.

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome.

Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, Klemann C, Fuchs I, Schuster V, von Bueren AO, Naumann-Bartsch N, Gambineri E, Siepermann K, Kobbe R, Nathrath M, Arkwright PD, Miano M, Stachel KD, Metzler M, Schwarz K, Kremer AN, Speckmann C, Ehl S, Mackensen A.

Blood. 2016 Jul 14;128(2):227-38. doi: 10.1182/blood-2015-11-685024. Epub 2016 Apr 20.

26.

CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis.

Braun M, Qorraj M, Büttner M, Klein FA, Saul D, Aigner M, Huber W, Mackensen A, Jitschin R, Mougiakakos D.

Leukemia. 2016 Aug;30(8):1788-92. doi: 10.1038/leu.2016.58. Epub 2016 Mar 8. No abstract available.

PMID:
26952837
27.

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC.

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.

PMID:
26884582
28.

NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation.

Jacobs B, Tognarelli S, Poller K, Bader P, Mackensen A, Ullrich E.

Front Immunol. 2015 Nov 24;6:583. doi: 10.3389/fimmu.2015.00583. eCollection 2015.

29.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
30.

Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation.

Böttcher M, Hofmann AD, Bruns H, Haibach M, Loschinski R, Saul D, Mackensen A, Le Blanc K, Jitschin R, Mougiakakos D.

Stem Cells. 2016 Feb;34(2):516-21. doi: 10.1002/stem.2234. Epub 2015 Nov 17.

31.

IL-7 Abrogates the Immunosuppressive Function of Human Double-Negative T Cells by Activating Akt/mTOR Signaling.

Allgäuer A, Schreiner E, Ferrazzi F, Ekici AB, Gerbitz A, Mackensen A, Völkl S.

J Immunol. 2015 Oct 1;195(7):3139-48. doi: 10.4049/jimmunol.1501389. Epub 2015 Aug 31.

32.

[What opportunities does Immuno-oncology indicate for overarching long-term survival?].

Bergmann L, Brugger W, Herr W, Mackensen A, Multhoff G.

Oncol Res Treat. 2015;38 Suppl 3:6-11. doi: 10.1159/000381363. Epub 2015 Apr 28. German. No abstract available.

33.

[Preface].

Hauschild A, Kölbl O, Mackensen A, Schadendorf D.

Oncol Res Treat. 2015;38 Suppl 3:1. doi: 10.1159/000381404. Epub 2015 Apr 28. German. No abstract available.

34.

Monitoring of hematopoietic chimerism by real-time quantitative PCR of micro insertions/deletions in samples with low DNA quantities.

Bach C, Tomova E, Goldmann K, Weisbach V, Roesler W, Mackensen A, Winkler J, Spriewald BM.

Transfus Med Hemother. 2015 Jan;42(1):38-45. doi: 10.1159/000370255. Epub 2014 Dec 22.

35.

Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.

Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J, Büttner M, Atreya I, Waldner M, Bittrich M, Lehmann CH, Rieger MA, Beilhack A, Zeiser R, Edinger M, Dudziak D, Mackensen A, Rehli M, Ullrich E.

Oncoimmunology. 2015 Feb 3;4(1):e981483. eCollection 2015 Jan.

36.

Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.

Bruns H, Büttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, Beier F, Pasemann S, Jitschin R, Hofmann AD, Neumann F, Daniel C, Maurberger A, Kempkes B, Amann K, Mackensen A, Gerbitz A.

Sci Transl Med. 2015 Apr 8;7(282):282ra47. doi: 10.1126/scitranslmed.aaa3230.

PMID:
25855493
37.

Contact-dependent depletion of hydrogen peroxide by catalase is a novel mechanism of myeloid-derived suppressor cell induction operating in human hepatic stellate cells.

Resheq YJ, Li KK, Ward ST, Wilhelm A, Garg A, Curbishley SM, Blahova M, Zimmermann HW, Jitschin R, Mougiakakos D, Mackensen A, Weston CJ, Adams DH.

J Immunol. 2015 Mar 15;194(6):2578-86. doi: 10.4049/jimmunol.1401046. Epub 2015 Feb 9.

38.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C.

Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15.

39.

[Forward: anti-tumor immunity and tumor immunology].

Hauschild A, Kölbl O, Mackensen A, Schadendorf D.

Oncol Res Treat. 2014;37 Suppl 4:1. doi: 10.1159/000366429. Epub 2014 Sep 30. German. No abstract available.

40.

Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency.

Rensing-Ehl A, Völkl S, Speckmann C, Lorenz MR, Ritter J, Janda A, Abinun M, Pircher H, Bengsch B, Thimme R, Fuchs I, Ammann S, Allgäuer A, Kentouche K, Cant A, Hambleton S, Bettoni da Cunha C, Huetker S, Kühnle I, Pekrun A, Seidel MG, Hummel M, Mackensen A, Schwarz K, Ehl S.

Blood. 2014 Aug 7;124(6):851-60. doi: 10.1182/blood-2014-03-564286. Epub 2014 Jun 3.

41.

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

Jitschin R, Braun M, Büttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, Oefner PJ, Le Blanc K, Mackensen A, Mougiakakos D.

Blood. 2014 Jul 31;124(5):750-60. doi: 10.1182/blood-2013-12-546416. Epub 2014 May 21.

42.

A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity.

Lux A, Seeling M, Baerenwaldt A, Lehmann B, Schwab I, Repp R, Meidenbauer N, Mackensen A, Hartmann A, Heidkamp G, Dudziak D, Nimmerjahn F.

Cell Rep. 2014 Apr 10;7(1):236-48. doi: 10.1016/j.celrep.2014.02.041. Epub 2014 Mar 27.

43.

Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.

Geisler K, Reischer A, Kroeger I, Jacobs B, Meinhardt K, Bauer R, Ryffel B, Mackensen A, Ullrich E.

Oncol Rep. 2014 May;31(5):2015-20. doi: 10.3892/or.2014.3070. Epub 2014 Mar 10.

PMID:
24626639
44.

Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia.

Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D.

Blood. 2014 Apr 24;123(17):2663-72. doi: 10.1182/blood-2013-10-532200. Epub 2014 Feb 19.

45.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D.

Lancet Oncol. 2014 Mar;15(3):297-304. doi: 10.1016/S1470-2045(14)70007-5. Epub 2014 Jan 31.

46.

Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany.

Aigner M, Bruns H, Gary R, Jitschin R, Kremer A, Mougiakakos D, Völkl S, Mackensen A, Gerbitz A.

Cancer Immunol Immunother. 2014 Feb;63(2):185-93. doi: 10.1007/s00262-013-1498-3. Epub 2013 Nov 5. No abstract available.

PMID:
24190547
47.

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

Schubert I, Saul D, Nowecki S, Mackensen A, Fey GH, Oduncu FS.

MAbs. 2014 Jan-Feb;6(1):286-96.

48.

High-resolution alkenone palaeobarometry indicates relatively stable pCO(2) during the Pliocene (3.3-2.8 Ma).

Badger MP, Schmidt DN, Mackensen A, Pancost RD.

Philos Trans A Math Phys Eng Sci. 2013 Sep 16;371(2001):20130094. doi: 10.1098/rsta.2013.0094. Print 2013 Oct 28.

49.

Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Dermatological Society; DermatologicCooperative Oncology Group.

J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126. doi: 10.1111/ddg.12113_suppl. English, German.

PMID:
24028775
50.

[Targeted therapy: old and new possibilities].

Hochhaus A, Lüftner D, Mackensen A.

Onkologie. 2013;36 Suppl 5:2-11. doi: 10.1159/000351997. Epub 2013 Jul 1. German. No abstract available.

Supplemental Content

Loading ...
Support Center